Chanock Lecture - Janet Englund
Bio
Dr. Englund's research interests include the study of vaccines and viral respiratory diseases in children, pregnant women, and immunocompromised hosts. She studies respiratory viral vaccines and novel methods of antiviral therapy for respiratory viruses including influenza, RSV, and SARS-CoV-2. She is a member of the Seattle Flu Study, has worked closely with Helen Chu MD, MPH, Trevor Bedford PhD, and other Seattle investigators in performing community and home-based respiratory viral surveillance and genomic monitoring of multiple respiratory viruses since 2019, and is currently active in the CDC-sponsored CASCADIA community-based study evaluating COVID-19 vaccine effectiveness. As a Clinical Associate at Fred Hutchinson Cancer Research Center, she is actively involved in studies of the prevention, treatment, and outcome of respiratory viral diseases in immunocompromised hosts. Dr. Englund's research group at Seattle Children's Hospital Research Institute is part of the New Vaccine Surveillance Network of the CDC, which assesses vaccine effectiveness of licensed vaccines in population-based studies. Her group has also been involved in research studies of maternal immunization with influenza, SARS-CoV-2, and RSV vaccines.
Dr. Englund has been a member of national and international organizations including the CDC-sponsored Advisory Committee on Immunization Practices (ACIP), the FDA Vaccines and Related Biological Products Advisory Committee (VRBAC), and vaccine safety groups at the World Health Organization. She is past president of the Society of Pediatric Infectious Diseases, past board member of the Infectious Diseases Society of America and the WHO Influenza working group, and currently active in the Influenza Working Group and SARS-CoV-2 Diagnostic Group of the Infectious Disease Society of America.
